These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
649 related articles for article (PubMed ID: 34712696)
1. Prognostic Value of N6-Methyladenosine-Related lncRNAs in Early-Stage Colorectal Cancer: Association With Immune Cell Infiltration and Chemotherapeutic Drug Sensitivity. Xiong Z; Li X; Yin S; Xie M; Mao C; Zhang F; Chen H; Jin L; Lian L Front Mol Biosci; 2021; 8():724889. PubMed ID: 34712696 [No Abstract] [Full Text] [Related]
2. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients. Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357 [TBL] [Abstract][Full Text] [Related]
3. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer. Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433 [TBL] [Abstract][Full Text] [Related]
4. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma. Zhao J; Lin X; Zhuang J; He F Front Genet; 2021; 12():714697. PubMed ID: 34777460 [No Abstract] [Full Text] [Related]
5. A N6-methyladenosine-related long noncoding RNAs model for predicting prognosis in oral squamous cell carcinoma: Association with immune cell infiltration and tumor metastasis. Yang Q; Cheng C; Zhu R; Guo F; Lai R; Liu X; Li M Oral Oncol; 2022 Apr; 127():105771. PubMed ID: 35189585 [TBL] [Abstract][Full Text] [Related]
6. Construction of a Novel Signature and Prediction of the Immune Landscape in Soft Tissue Sarcomas Based on N6-Methylandenosine-Related LncRNAs. Zhang L; Tang X; Wan J; Zhang X; Zheng T; Lin Z; Liu T Front Mol Biosci; 2021; 8():715764. PubMed ID: 34733885 [No Abstract] [Full Text] [Related]
7. N6-Methyladenosine-Related Long Non-coding RNA Signature Associated With Prognosis and Immunotherapeutic Efficacy of Clear-Cell Renal Cell Carcinoma. Ma T; Wang X; Wang J; Liu X; Lai S; Zhang W; Meng L; Tian Z; Zhang Y Front Genet; 2021; 12():726369. PubMed ID: 34721523 [TBL] [Abstract][Full Text] [Related]
8. Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma. Qiu Y; Wang X; Fan Z; Zhan S; Jiang X; Huang J Immun Inflamm Dis; 2021 Dec; 9(4):1596-1612. PubMed ID: 34432955 [TBL] [Abstract][Full Text] [Related]
9. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients. Xu S; Chen W; Wang Y; Zhang Y; Xia R; Shen J; Gong X; Liang Y; Xu J; Tang H; Zhao T; Zhang Y; Chen T; Wang C BMC Cancer; 2022 Jul; 22(1):721. PubMed ID: 35778697 [TBL] [Abstract][Full Text] [Related]
10. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer. Song Y; Qu H BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis of N6-Methyladenosine-Related IncRNAs Prognostic Signature and the Associated Immune Infiltrates in Kidney Renal Clear Cell Carcinoma. Chen X; Wang L; Tu J; Pan X; Li Y; Yin H; Wang M; Yuan X Crit Rev Eukaryot Gene Expr; 2022; 32(1):79-98. PubMed ID: 35377983 [TBL] [Abstract][Full Text] [Related]
12. Construction and validation of N6-methyladenosine long non-coding RNAs signature of prognostic value for early biochemical recurrence of prostate cancer. Liu J; Zhang W; Wang J; Lv Z; Xia H; Zhang Z; Zhang Y; Wang J J Cancer Res Clin Oncol; 2023 May; 149(5):1969-1983. PubMed ID: 35731271 [TBL] [Abstract][Full Text] [Related]
13. Identification and Validation of a Novel 2-LncRNAs Signature Associated with m6A Regulation in Colorectal Cancer. Wang K; Zhao B; Liang Y; Ma B J Cancer; 2022; 13(1):21-33. PubMed ID: 34976168 [TBL] [Abstract][Full Text] [Related]
14. Identification of N6-methylandenosine related lncRNA signatures for predicting the prognosis and therapy response in colorectal cancer patients. Li Z; Liu Y; Yi H; Cai T; Wei Y Front Genet; 2022; 13():947747. PubMed ID: 36246627 [TBL] [Abstract][Full Text] [Related]
15. Identification of a novel m6A-related lncRNA pair signature for predicting the prognosis of gastric cancer patients. Wang JM; Li X; Yang P; Geng WB; Wang XY BMC Gastroenterol; 2022 Feb; 22(1):76. PubMed ID: 35189810 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Drug Targets Predicted Using Deep Bioinformatic Analysis of m6A-Associated lncRNA-Based Pancreatic Cancer Model Characteristics and Its Tumour Microenvironment. Cao PW; Liu L; Li ZH; Cao F; Liu FB Front Genet; 2022; 13():853471. PubMed ID: 35547245 [TBL] [Abstract][Full Text] [Related]
17. Construction and Analysis of a Colorectal Cancer Prognostic Model Based on N6-Methyladenosine-Related lncRNAs. Zeng H; Xu Y; Xu S; Jin L; Shen Y; Rajan KC; Bhandari A; Xia E Front Cell Dev Biol; 2021; 9():698388. PubMed ID: 34490250 [TBL] [Abstract][Full Text] [Related]
18. Construction of an N6-methyladenosine lncRNA- and immune cell infiltration-related prognostic model in colorectal cancer. Yu ZL; Zhu ZM Protoplasma; 2022 Jul; 259(4):1029-1045. PubMed ID: 34734333 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive Analysis of N6-Methyladenosine-Related lncRNA Signature for Predicting Prognosis and Immune Cell Infiltration in Patients with Colorectal Cancer. Zhao Z; Yang YB; Li XY; Li XG; Chu XD; Lin ZB; Zhang YR; Guo YG; Ding H; Pan YL; Wang L; Pan JH Dis Markers; 2021; 2021():8686307. PubMed ID: 34745388 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer. Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]